Influence of SARS-CoV-2 mRNA Vaccine Booster among Cancer Patients on Active Treatment Previously Immunized with Inactivated versus mRNA Vaccines: A Prospective Cohort Study

3Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Cancer patients on chemotherapy have a lower immune response to SARS-CoV-2 vaccines. Therefore, through a prospective cohort study of patients with solid tumors receiving chemotherapy, we aimed to determine the immunogenicity of an mRNA vaccine booster (BNT162b2) among patients previously immunized with an inactivated (CoronaVac) or homologous (BNT162b2) SARS-CoV-2 vaccine. The primary outcome was the proportion of patients with anti-SARS-CoV-2 neutralizing antibody (NAb) seropositivity at 8–12 weeks post-booster. The secondary end points included IgG antibody (TAb) seropositivity and specific T-cell responses. A total of 109 patients were included. Eighty-four (77%) had heterologous vaccine schedules (two doses of CoronaVac followed by the BNT162b2 booster) and twenty-five had (23%) homologous vaccine schedules (three doses of BNT162b2). IgG antibody positivity for the homologous and heterologous regimen were 100% and 96% (p = 0.338), whereas NAb positivity reached 100% and 92% (p = 0.13), respectively. Absolute NAb positivity and Tab levels were associated with the homologous schedule (with a beta coefficient of 0.26 with p = 0.027 and a geometric mean ratio 1.41 with p = 0.044, respectively). Both the homologous and heterologous vaccine regimens elicited a strong humoral and cellular response after the BNT162b2 booster. The homologous regimen was associated with higher NAb positivity and Tab levels after adjusting for relevant covariates.

References Powered by Scopus

An interactive web-based dashboard to track COVID-19 in real time

7052Citations
N/AReaders
Get full text

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

2758Citations
N/AReaders
Get full text

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

2744Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Pathophysiological, immunological, and inflammatory features of long COVID

12Citations
N/AReaders
Get full text

Neutralizing antibodies and safety of a COVID-19 vaccine against SARS-CoV-2 wild-type and Omicron variants in solid cancer patients

0Citations
N/AReaders
Get full text

Comparison of long-term anti-RBD SARS-CoV-2 antibody response following different vaccination schemes in Tunisia

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Mondaca, S., Walbaum, B., Le Corre, N., Ferrés, M., Valdés, A., Martínez-Valdebenito, C., … Nervi, B. (2023). Influence of SARS-CoV-2 mRNA Vaccine Booster among Cancer Patients on Active Treatment Previously Immunized with Inactivated versus mRNA Vaccines: A Prospective Cohort Study. Vaccines, 11(7). https://doi.org/10.3390/vaccines11071193

Readers' Seniority

Tooltip

Professor / Associate Prof. 1

50%

Lecturer / Post doc 1

50%

Readers' Discipline

Tooltip

Immunology and Microbiology 2

100%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free